Kisplyx (Lenvatinib)

Lenvatinib blocks multiple receptor tyrosine kinases such as VEGFR1‑3, FGFR1‑4, PDGFRα, KIT and RET. Inhibiting these receptors reduces angiogenesis, cell proliferation and survival signals, thereby slowing tumour growth and spread.

The dose of Kisplyx is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the exact dosing instructions provided by their healthcare professional.

Safety data for Lenvatinib in pregnant or nursing women are limited. The drug may pose risks to the fetus and infant, and it is generally advised to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk. Consultation with a specialist is essential.

To request Kisplyx, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kisplyx (Lenvatinib) targets a broader spectrum of kinases, including VEGFR, FGFR, PDGFR, KIT and RET, compared with some alternatives that may focus on fewer receptors. This broader inhibition can offer therapeutic advantages in tumours driven by multiple pathways, but the safety profile and drug‑interaction potential also differ.

Kisplyx should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Kisplyx is taken orally, usually as a tablet, with or without food as directed by the treating physician. The exact timing and frequency are determined by the prescriber based on the individual treatment plan.

Serious risks include hepatic failure, severe bleeding, gastrointestinal perforation and cardiac dysfunction. Patients should be monitored regularly for signs of liver injury, abnormal bleeding, abdominal pain or heart‑related symptoms, and any concerning findings should be reported to a healthcare professional immediately.

Kisplyx is contraindicated in patients with known hypersensitivity to Lenvatinib or any of its excipients. Caution is also advised for individuals with uncontrolled hypertension, severe hepatic impairment, or those taking strong CYP3A4 inhibitors or anticoagulants without appropriate monitoring.